Supernus Pharma (SUPN) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Supernus Announces Fourth Quarter and Full Year 2014 Results
March 10, 2015 5:00 PM EDTCash flow positive for the fourth quarter, $5.9 million, and for the full year, $3.2 million. Â Net income for the fourth quarter, $4.4 million, and for the full year, $19.9 million. Â Total revenue for the fourth quarter, $30.8 million, exceeded guidance by $4 million, and includes $30.5 million in net product sales. Â Total revenue for full year 2014 was $122.0 million, including $89.6 million in net product sales. Â Fourth quarter product prescriptions increased to 70,739, representing a 22% increase over the third quarter of 2014. Â Met with the FDA in December to review SPN-810. We remain on-track to initiate Phase III testing in the fourth quarter of... More
Supernus Announces Fourth Quarter and Full Year 2014 Results
March 10, 2015 5:00 PM EDTCash flow positive for the fourth quarter, $5.9 million, and for the full year, $3.2 million. Â Net income for the fourth quarter, $4.4 million, and for the full year, $19.9 million. Â Total revenue for the fourth quarter, $30.8 million, exceeded guidance by $4 million, and includes $30.5 million in net product sales. Â Total revenue for full year 2014 was $122.0 million, including $89.6 million in net product sales. Â Fourth quarter product prescriptions increased to 70,739, representing a 22% increase over the third quarter of 2014. Â Met with the FDA in December to review SPN-810. We remain on-track to initiate Phase III testing in the fourth quarter of... More
